








EAN ECONOMIC EVALUATION OF 
THE PRISON METHADONE
PROGRAM IN NEW SOUTH WALES
Project Report
Emma Warren, Rosalie Viney
Project Report 22
January 2004II
AN ECONOMIC EVALUATION OF THE PRISON METHADONE PROGRAM IN NEW SOUTH WALES
The Centre for Health Economics Research and Evaluation (CHERE) was established in 1991.
CHERE is a centre of excellence in health economics and health services research. It is a joint Centre
of the Faculties of Business and Nursing, Midwifery and Health at the University of Technology,
Sydney, in collaboration with Central Sydney Area Health Service. It was established as a UTS Centre
in February, 2002. The Centre aims to contribute to the development and application of health
economics and health services research through research, teaching and policy support.
CHERE’s research program encompasses both the theory and application of health economics. The
main theoretical research theme pursues valuing benefits, including understanding what individuals
value from health and health care, how such values should be measured, and exploring the social
values attached to these benefits. The applied research focuses on economic and the appraisal of
new programs or new ways of delivering and/or funding services.
CHERE’s teaching includes introducing clinicians, health services managers, public health
professionals and others to health economic principles. Training programs aim to develop practical
skills in health economics and health services research.
Policy support is provided at all levels of the health care system by undertaking commissioned
projects, through the provision of formal and informal advice as well as participation in working
parties and committees. ACKNOWLEDGEMENTS 
Funding was provided by the National Health and Medical Research Council. We are grateful to
clinical, custodial and administrative staff at NSW Corrections Health Service, the NSW Department
of Corrective Services and our particular thanks for the support and advice of Dr Richard Matthews
and Ms Sharon Barton at NSW Corrections Health Service. The views expressed in this report do not
necessarily reflect those of the funders, the NSW Corrections Health Service, the NSW Department
of Corrective Services or anyone who provided assistance to the study.
COLLABORATING COLLEAGUES
NDARC (National Drug and Alcohol Research Centre) 





St Vincent’s Hospital, Sydney
Alex Wodak
III
AN ECONOMIC EVALUATION OF THE PRISON METHADONE PROGRAM IN NEW SOUTH WALESIV
AN ECONOMIC EVALUATION OF THE PRISON METHADONE PROGRAM IN NEW SOUTH WALES
EXECUTIVE SUMMARY
Objectives 
The aim of this study is to evaluate the costs and consequences of the provision of the prison
methadone program in NSW, compared with no prison methadone. 
Methods
This study has measured the costs involved in the provision of the prison methadone program in
NSW. The overall cost of the prison methadone program was estimated from a governmental
perspective, incorporating the costs associated with the administration of the program, staffing
requirements, methadone syrup and consumables. Both bottom-up and top-down costing
approaches have been used. Both the total cost of the program and the cost per inmate in treatment
are presented. 
The study is based on a follow-up study of a randomised trial of prison methadone in the NSW prison
system (Dolan, Shearer et al. 2003). Although methadone is available to prisoners in many NSW
prisons, the aim of the trial was to determine the impact of prison methadone on a range of health
and social outcomes. Participants were randomised to receive prison methadone immediately or to
be waitlisted. Waitlisted inmates were offered methadone after a four month delay. The cohort
recruited by Dolan et al is now the subject of a four year follow-up study. Since all subjects had been
offered methadone at the conclusion of the RCT, this could no longer be treated as controlled study.
This limits the utility of the study outcome data for the economic evaluation.
In the absence of comparative outcome data, a threshold analysis has been performed to determine
what magnitude of outcomes is required to render the prison methadone program cost-neutral from
a governmental perspective. The threshold analysis assumes that, through the provision of prison
methadone, patients will gain from the benefits associated with continuous methadone treatment.
Thus future criminal activity will be reduced and re-incarceration may be avoided. The analysis
determines how many days of re-incarceration must be avoided to offset the annual cost of the
methadone program. Firstly the analysis estimates what additional resources are required in the
prison system to deliver prison methadone. Secondly, potential cost savings associated with avoided
re-incarceration are estimated. The costs of the prison methadone program are then compared with
the cost savings accrued by avoided days of re-incarceration and the level of effectiveness required to
equate costs and savings is identified. A second threshold analysis assumes that, in addition to
avoiding days of re-incarceration, prison methadone also avoids incident cases of Hepatitis-C. Given
the cost of the program and the number of avoided cases of Hepatitis-C, the threshold analysis
identifies the level of effectiveness, in terms of avoided re-incarceration, at which methadone
treatment becomes cost neutral.
Results 
The total cost of providing prison methadone to 900 inmates in 21 prisons in NSW is $2.9million per
annum. The cost per person year is $3,234. Given that the average daily cost of incarceration is $176,
the annual cost of prison methadone is offset by avoiding 20 days of re-incarceration once the inmate
is released. If avoided incident cases of hepatitis-C are included in the analysis, the annual cost of
prison methadone is offset by avoiding 19 days of re-incarceration once the inmate is released.
Conclusions
This analysis shows that, despite significant barriers to efficiency, prison methadone compares
favourably to community based methadone on the basis of cost alone. The analyses suggests that,
irrespective of whether avoided cases of Hepatitis-C are included, approximately 20 days of re-
incarceration must be avoided to offset the annual cost of methadone treatment. There appears to be
no evidence in the literature to prove or disprove the feasibility of prison methadone maintenance
avoiding such a period of re-incarceration.AN ECONOMIC EVALUATION OF THE PRISON METHADONE 
PROGRAM IN NEW SOUTH WALES
1. INTRODUCTION
Methadone maintenance has been found to reduce heroin use, reduce drug-related crime, prevent
HIV infection and reduce mortality among IDUs (Schoenbaum, Hartel et al. 1989; Caplehorn, Dalton
et al. 1994; Hall, Ward et al. 1998). Methadone therapy has been shown to be most efficacious at
reducing heroin use and associated harms when treatment is continuous. Evidence suggests that
continued methadone therapy is associated with better outcomes (Simpson 1979; French, Zarkin et
al. 1993). These studies suggest that heroin use and criminal activities are reduced in patients
undergoing longer periods of methadone therapy. In addition, arbitrary termination of methadone
therapy has been shown to be associated with poor treatment outcomes (Anglin, Speckart et al.
1989).
By this rationale, cessation of methadone therapy on entry into prison is likely to be associated with
poor outcome prognosis. Thus a case exists for methadone maintenance therapy to be made
available in prisons in order to maximise the potential treatment outcomes associated with
continuous methadone therapy. 
Prison methadone programs are relatively rare and little is known about their effectiveness or cost-
effectiveness. There are no published studies detailing the effectiveness or cost-effectiveness of
prison methadone programs. However, there are several economic evaluations of community
methadone programs. The majority of these economic evaluations are US based (Barnett 1999;
Zaric, Barnett et al. 2000). Both studies used modelling techniques and found community
methadone programs to be cost-effective. 
The aim of the current study is to examine the costs and consequences of the New South Wales
(NSW) prison methadone maintenance program. The NSW prison methadone program began in
1986 as a pre-release program which targeted IDUs with multiple periods of incarceration. In the late
1980s, the prison methadone program underwent a rapid expansion. The NSW prison methadone
program has since moved beyond pre-release towards offering methadone maintenance therapy. In
2003, there were 24 prisons in NSW, 21 of which provided methadone maintenance treatment to
inmates. In NSW in 2003, the total number of inmates receiving methadone per day was
approximately 1000. However ten percent of these received methadone in police and court cells etc.
Thus approximately 900 inmates receive daily methadone treatment in NSW prisons.
Economic evaluations can assist policy makers to determine which programs should receive priority
given these limited resources. An economic evaluation proceeds by identifying, quantifying and
valuing the costs and consequences of the program under review. The main types of economic
evaluations in health services are: cost minimisation analysis (CMA), cost-effectiveness analysis
(CEA), cost-utility analysis (CUA) and cost-benefit (CBA). The majority of economic evaluations
performed in the health economics setting have been cost-effectiveness analyses. By definition, a
cost-effectiveness analysis requires the identification of a single outcome e.g. cost per life year saved
or cost per event avoided. However, with prison methadone programs, it is possible to identify several
outcomes associated with treatment; reduced heroin use, the prevention of communicable diseases
such as HIV and HCV and a reduction in re-incarceration rates. Therefore, a key challenge when
performing an economic evaluation of prison methadone programs is the identification of the
appropriate outcomes to be used in the analysis. A further challenge is the limited data available on
the outcomes of prison methadone programs.
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The study is based in part on the results of a randomised trial of prison methadone conducted in
NSW (Dolan, Shearer et al. 2003). This report provides a summary of the trial, describes the resource
utilisation associated with the NSW prison methadone program and estimates the cost of such
utilisation. A threshold analysis is used to determine the level of outcome required to render the
prison methadone program a cost-effective treatment option. Section two of the report provides
details of the first randomised controlled trial of methadone maintenance treatment within a prison
community (Dolan, Shearer et al. 2003). Section three details the methods used in the economic
analysis. Sections four and five report the results of the costing and the threshold 
analyses respectively. 3
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2. EFFECTIVENESS OF PRISON METHADONE
Dolan et al (Dolan, Shearer et al. 2003) details the results of a randomised controlled trial of
methadone maintenance treatment within the NSW prison community. The aim of the trial was to
examine the impact of prison methadone on a) prevalence and frequency of heroin injecting, b)
heroin use, c) incidence of HIV and hepatitis C (HCV) and d) re-incarceration. The study was an open,
two-group, randomised controlled trial.
382 inmates were either randomised into treatment or control conditions. Inmates in the treatment
group joined the prison methadone program immediately. Inmates in the control group were placed
on a four-month waitlist for the prison methadone program with guaranteed access after that
period. The trial was constrained to this design because at the time of the study the waitlist for the
prison methadone program was six months. Subjects were reinterviewed four months after their
first interview. 
At baseline, recruits in both groups were comparable on all key demographic characteristics, prison
histories, injecting drug use and sharing of injecting equipment. The mean age in both groups was
27 years and daily injecting had commenced at mean age 19.  Baseline HIV was zero for both groups.
Baseline HCV prevalence was 76% and 72% for treated and control subjects. Further details on the
Dolan trial can be found elsewhere (Dolan, Shearer et al. 2003). 
The cohort recruited by Dolan et al in 1997/98 is now the subject of a four year follow-up study
(Dolan, Shearer et al. (manuscript in preparation)). Since all subjects had been offered methadone at
the conclusion of the RCT, this could no longer be treated as controlled study. This limits the utility of
the study outcome data for the economic evaluation.
When analysing the follow-up study by original randomisation group, the incidence of hepatitis-C was
lower in the treated group, 24 versus 32 cases per 100 person years (Personal communication). This
suggests that prison methadone reduces the incidence of HCV. However, this difference was not
statistically significant. Although not statistically significant, it is notable that the difference in HCV
incidence has persisted through the four years of follow-up, despite the fact that the difference in
methadone treatment was only four months. This provides support for the argument that prison
methadone, as part of an overall program of methadone provision, is an important part of a harm
minimisation strategy. At follow-up, the prevalence of HIV was 3% and 1% in the treated and control
groups. This difference was not statistically significant.
One likely reason for the finding of no significant difference between the treatment and control
groups is the relatively high prevalence of HCV and low prevalence of HIV in the NSW prison
population. A further reason is the constraint placed on the trial design by the need to use a waitlist
control. Inmates in the control arm had guaranteed access to methadone after four months. This
resulted in a large proportion of the control arm receiving methadone therapy relatively soon after
randomisation. Approximately 70% of the total cohort had received methadone treatment within 6
months of randomisation. In addition, the sample size of the trial was designed to detect a difference
in heroin use. Thus the original trial was not sufficiently powered to detect a significant difference in
HCV or HIV incidence (Dolan, Shearer et al. 2003).4
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The difference in re-incarceration results did not reach statistical significance when analysed by
original randomisation group. However the difference in re-incarceration rates did reach statistical
significance when the cohort was divided into those with continuous treatment and those without
(Personal communication). Continuous treatment represents those currently in their one and only
treatment episode (i.e. those who never started methadone, those who started methadone but have
since stopped treatment and those who have had more than one treatment episode would be in the
non-continuous group).
Table 1: Rates of re-incarceration
CONTINUOS NON-CONTINUOUS P VALUE
Mean wks to first re-incarceration 82 53 0.001
Mean total wks in prison (sd) 52 (58) 71 (57) 0.0025
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3. OVERVIEW OF METHODS
This study models the cost and health consequences of the NSW prison methadone program. The
analysis is based on data from the current program. This analysis estimates the cost of providing a
methadone program to relatively non-transitory inmates. As described above, this represents 90% of
the population currently receiving prison methadone in NSW, that is, those inmates who are not in
police and court cells. Therefore the model estimates the cost of providing daily methadone to a pool
of 900 inmates in NSW prisons, taking into account the rate of entry and exit to this pool. 
The economic evaluation is performed from a government perspective. The provision of most of the
services involved in the NSW prison methadone program is funded by the NSW government, but the
provision of the methadone syrup itself is funded by the Commonwealth government through the
Pharmaceutical Benefits Scheme (PBS).
The resources employed in the provision of prison methadone include the administration of the
program, staffing requirements, methadone syrup and consumables. This study identifies and costs
these resources. The analysis uses a combination of both the bottom-up and top-down approach
when estimating the total cost of the program. The assessment of Corrections Health Service (CHS)
administration costs uses a top-down approach whilst the assessment of costs associated with
nurse/doctor time uses a bottom-up costing approach. The bottom-up costing is based upon
observation visits to four prison clinics and interviews with nurses, doctors and CHS staff. It is
assumed that the observed clinics are typical, and that those clinics not observed operate in a similar
manner. 
In most economic evaluations of healthcare interventions it is standard practice to include an
analysis of the treatment outcomes. Therefore, an economic evaluation of prison methadone ideally
would incorporate treatment outcomes such as avoided re-incarceration once inmates are released
or avoided incidence of HCV.
For the reasons discussed above, the results from the NSW prison methadone follow-up study
(Dolan, Shearer et al. (manuscript in preparation)) cannot be used in an analysis assessing the cost-
effectiveness of methadone when compared with no treatment. In addition, there is little evidence in
the literature relating to HCV incidence and re-incarceration rates for those patients receiving
methadone maintenance therapy in prison. Therefore, a threshold analysis has been performed to
determine what societal benefits must be accrued by prison methadone to render the NSW prison
methadone program a cost-effective treatment option. A model was constructed that identifies the
level of effectiveness required from methadone treatment, in terms of avoided cases of HCV and
avoided re-incarceration, to offset the costs of the treatment itself.
Cost of management and administration of the prison methadone program
Two levels of administration within Corrections Health Service (CHS) are involved in the management
of the prison methadone program and hence should be included in the cost analysis. The first level is
general CHS administration, including the Chief Executive Officer of CHS and the finance, payroll and
IT departments. The second level is the administration of the methadone program itself. 
The NSW prison methadone program comes under the supervision and management of the drug
and alcohol department within CHS. There are six members of CHS staff involved in the
management and administration of the NSW prison drug and alcohol program of which the
methadone program is a major component: the Director of the drug and alcohol department, 3
clinical nurse consultants (CNC), one administrative officer and one information officer. One clinical
nurse consultant works solely on the methadone program, and 100% of salary costs are attributed to
the methadone program. The duties of the two remaining clinical nurse consultants, one for drug
and alcohol and one for pharmacotherapy include all drug and alcohol related issues. Therefore, it is
likely that they also perform some methadone-related work.6
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Both the methadone clinical nurse consultant and the administrative post work in the liaison office.
The liaison office at the NSW remand and reception facility deals with the administration of all exits
from prison and locates community methadone programs for soon-to-be released inmates. For
those inmates who cannot be placed on a community methadone program, the liaison staff organise
the extension of methadone prescriptions. This involves obtaining a prescription from a prison doctor
and sending it to a community pharmacy.
Cost of general CHS administration
The cost of CHS administration accounts for 8% of the total CHS annual budget (CHS Finance
Department). It is assumed that the administrative costs of the methadone program will be in
proportion to that of other CHS activities, and therefore that 8% of the total methadone budget
represents methadone-related administration. Because this administration covers both transient
and non-transient inmates, it is assumed that only 90% of this cost is attributable to the delivery of
prison methadone. 
The annual CHS methadone budget is $1.76 million (CHS Finance Department).  The amount of CHS
administration costs attributable to non-transient methadone inmates is $126,720.
Cost of managing the methadone program
As previously described, there are six members of CHS staff involved in the management and
administration of the methadone program.  The model assumes that the Director of the drug and
alcohol department, the two non-methadone clinical nurse consultants and the information officer
spend 50% of their time on methadone-related issues. Thus 50% of their annual salaries are
attributed to the program. Since one clinical nurse consultant works solely on the methadone
program, 100% of the salary is attributed to the program costs.
The work performed in the liaison office is performed by one part-time clinical nurse consultant and
one full-time administrative post. The nurse spends approximately 95% of her time is methadone-
related work (5% is spent on buprenorphine). The hourly rate of the CNC is $35.98. The administrator
in the liaison office works full-time and attributes 95% of her time to methadone-related issues. The
salary of the liaison administrator is $31,000. The hourly rate of the liaison administrator is $15.69. 
Ten percent of this administration cost is excluded to represent the 100 transient inmates receiving
daily methadone in police and court cells.
The liaison office uses two computers, a FAX machine, a photocopier and sends 100 pages through
FAX per working day. The unit costs associated with this equipment are shown in Appendix 1. These
costs have not been included in the analysis since IT and equipment is included in the CHS
administration budget. 
Cost of nurse time
In addition to the CNCs, registered nurses assess inmates and administer the methadone. The
assessment of nurse time is based upon observational visits to the four prison clinics and interviews
with nurses, doctors and Corrections Health staff.
Methadone parade
The process of dosing varies between the different prisons. However, there are some similarities.
Dosing requires two nurses (one to dose and one to record the dosage). Preparation for and closing
of the dosing parade, which includes counting and recording remaining methadone and keeping the
records, requires two nurses for approximately 30 minutes at the beginning and 30 minutes at the
end of each dosing parade. Since two nurses are involved and 21 clinics are performing this activity
on a daily basis, a total of 15,330 nursing hours per year are spent on this activity.
The dosing itself is either performed at the central clinic, at satellite clinics or in the wings
themselves. The total dosing time ranged from approximately 50 minutes to 3.5 hours for this work. 7
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The following table shows the number of nurse hours, per day and per inmate, associated with
dosing in each of the observed clinics. Based on an observation of four prison clinics, average dosing
requires six minutes and 15 seconds of nurse time per inmate.
Table 2: Nurse hours associated with dosing
PRISON NO. PATIENTS DURATION NO. NURSES NURSE HOURS NURSE HOURS MINUTES 
PER INMATE PER INMATE
A4 12 24 0.098 5 mins 53 sec
B 100 3.5 2 7 0.070 4 mins 12 sec
C6 1 3.5 2 7 0.115 6 mins 54 sec
D1 3 0.875 2 1.75 0.135 8 mins 6 sec
Total 215 0.104 6 mins 15 sec
Notes:  1. The times reported here exclude preparation time. 
2. Night dosing that occurs at the remand centre has been excluded. 
There are approximately 900 inmates receiving methadone on a daily basis. Assuming that dosing of
methadone requires six minutes and 15 seconds nurse time per inmate, the total daily number of
nurse hours associated with the methadone parade is 93.81 per day. This equates to 34,240 nurse
hours per year (or 17 full time equivalent nurses).
The central estimate assumes that dosing requires an average of six minutes and 15 seconds of
nurse time per inmate. However, it is evident from Table 2 that the duration of required nurse 
time ranges from 4 minutes to 8 minutes per inmate depending on the prison. Therefore, the
sensitivity analysis was used to determine the effect of varying the average duration of dosing 
from 4 to 8 minutes. 
It should also be noted that the use of a weighted average was deemed inappropriate. The averaging
method used in this report gives equal weighting to all prisons. Since it is unknown whether the four
clinics observed are a representative sample of the NSW prison system, a simple average was
considered more appropriate than a weighted average, which would give more weight to those
prisons with higher numbers of inmates on methadone. 
Buprenorphine is also dosed during this time. However, at the four clinics observed, few patients
received buprenorphine. Since the dosing of buprenorphine is unlikely to have a significant effect on
the total number of nurse hours associated with the dosing of methadone, it was decided that the
dosing duration observed would be used in the analysis. 
Ongoing management of patients 
In addition to the methadone parade nurses have other responsibilities. If an inmate requests an
increase or decrease in dose outside the range defined by the Medical Officer, the nurse prepares
the paperwork so that the doctor can amend the treatment sheet. This process requires
approximately 10 to 15 minutes of nurse time.  If an inmate is transferred to another prison, the role
of the nurse is to transfer all the details relating to the treatment and dosing of the inmate to the new
prison. The gathering and sending of information requires about 30 minutes per inmate.8
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The majority of the prisons (except the reception / remand centre) do not have a nurse specifically
allocated to methadone treatment. The reception / remand centre is the only prison with a full-time
methadone nurse. All methadone duties are performed by the same nurse at this prison. The main
reason why this prison requires a full-time methadone nurse is due to the reception/remand nature
of the prison. Since the prison is a reception centre, there are approximately 3-5 new receptions per
night on a methadone program. It is the job of the methadone nurse to check the inmate’s details so
that they can be dosed.  During the standard interview by a nurse during reception, new inmates are
asked whether they were enrolled in a methadone program in the community. If new inmates were
receiving methadone, details relating to their prescribing clinic, dose and duration of treatment are
taken. The process of confirming all the details can take between 5 and 30 minutes. If the details are
correct, the inmate is eligible for methadone and can be dosed the next day. 
Table 3 shows the number of nurse hours per week spent on paperwork for each of the observed
clinics. The use of a weighted average when estimating the number of hours per inmate was, again,
deemed inappropriate.
Table 3: Nurse hours associated with paperwork 
PRISON NO. PATIENTS HOURS PER WEEK HOURS PER INMATE PER WEEK MINUTES PER INMATE
A4 11 0 0.244 14 mins 38 secs
B 100 11.25 0.113 6 mins 45 secs
C6 13 0.049 2 mins 56 secs
D1 32 0.154 9 mins 14 secs
Total 215 0.140 8 mins 25 secs
Since 900 inmates are regularly receiving methadone, a total of 126 nurse hours per week are spent
on paperwork. This equates to 6546 nurse hours per year.
Assessments
If an inmate applies to commence methadone treatment, the inmate undergoes an assessment
interview to assess their eligibility. This assessment is usually performed by a nurse. The duration of
this assessment ranges from 20 minutes to one hour. If the nurse is satisfied that the inmate is
eligible for methadone treatment, the inmate has a consultation with the doctor. 
When an inmate on methadone is soon to be released from prison, the nurse performs an exit
interview. The interview requires one nurse and the duration is approximately 30 minutes.
In 2001, 762 inmates commenced methadone treatment whilst in custody and 1,828 inmates were
released from prison on methadone (CHS Annual Report). Therefore, excluding any assessments
due to other reasons, nurses performed 2590 assessments in 2001. Since each assessment requires
approximately 30 minutes, entry and exit assessments require 1295 hours of nurse time per annum.9
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The estimate of total number of nurse hours per annum spent on Methadone across the various jails
was 57,411 as is seen in Table 4. The annual number of nurse hours was multiplied by the hourly
rate to determine the total annual cost of nurse time attributed to the prison methadone program.
The vast majority of nurses involved in the methadone program are grade RN8 with an hourly rate of
an RN8 in Correction Health of $28.12.
Table 4: Nurse hours associated with methadone-related issues
NURSING ACTIVITY  NURSING HOURS
Methadone parade (preparation, clear up and dosing  49,570
Assessment 1,295
Paperwork 6,545
Total nursing hours  57,411
Cost of doctor time (including cost of drug and alcohol staff specialist)
Doctors’ involvement
Most prisons do not have a doctor who is solely responsible for drug and alcohol problems. The
majority of the prisons have a Medical Officer (MO), visiting or career, who deals with all health
issues. Approximately 90% of the Medical Officers in NSW prisons are Visiting Medical Officers and
most are also methadone prescribers. However, some MOs do not have the authority to prescribe
methadone. In this situation, either the prison does not offer methadone to its inmates or
prescriptions may be written by another doctor in another prison (usually the drug and alcohol
doctors at reception / remand prison). New scripts detailing increases/decreases in dose will also be
received from the drug and alcohol doctors at reception / remand prison. 
Usually methadone-related work is a small proportion of the VMO/CMO’s total work load. In general,
the VMO/CMO at a prison has very little methadone-related face-to-face contact with inmates other
than the initial interview when an inmate commences methadone. The majority of the doctor’s
involvement in prison methadone is administrative. VMOs spend approximately 1 hour per week on
methadone-related work and two thirds of this time is spent on paperwork i.e. checking and writing
scripts (Personal communication with clinic VMO). 
The reception / remand prison has a full-time drug and alcohol staff specialist to deal with the high
volume of new inmates and prescriptions. It is estimated that this staff specialist spends
approximately 90% of their time on methadone-related work.  
The hourly rate for a Visiting Medical Officer is $146.75 whilst the hourly rate for a Career Medical
Officer is $56.14. It is assumed that medical officers at each clinic spend 1 hour per week on
methadone-related work. Therefore a total of approximately 983 VMO hours and approximately 109
CMO hours are attributed to the methadone program per year.
Since the drug and alcohol staff specialist spends 90% of her time of methadone-related work, 34
hours per week are spent on methadone issues. The hourly rate for a drug and alcohol staff
specialist is $54.62. Cost of correctional officers
Correctional officers transport inmates to and from the clinics and supervise the methadone parade.
However, the costs associated with the correctional officers’ time have not been included in the
central estimate. The number of correctional officers employed in any one prison is based on the
security needs of the prison (based on the number of inmates). Thus the correctional officers
working on the methadone parade would still be employed at the prison if the methadone program
was not operational. Therefore the opportunity cost associated with correctional officers’ time is 
zero. For this reason, the costs associated with the correctional officers’ time have been excluded
from the cost of the methadone program in the central estimate. However, the sensitivity analysis
examines the effect on the total cost of including the costs associated with correctional officers’ time
in the analysis.
Cost of pharmacy (including the cost of courier)
Long Bay Correctional Centre houses the pharmacy for NSW prisons. The prison clinics order
methadone once a week and methadone is delivered by courier weekly. The estimated time spent in
handling methadone over a twelve month period is shown in Table 5 (Personal communication with
Pharmacy staff).
Table 5: Pharmacy methadone-related hours
TASKS APPROX. HOURS - YEARLY
Ordering – place order every three weeks _ hour 8.5
Storage – every three weeks 20 minutes 5.5
Auditing – pharmacy daily 52.0
Dispensing – filling orders for all clinics and wards 208.0
Packing – orders to all clinical and wards weekly 208.0
Data entry weekly 26.0
Auditing – twice yearly of S8 registers 26.0
Total 534.0
326 hours of pharmacist time and 208 hours of dispenser time are attributed to the methadone
program per annum. The hourly rate of a pharmacist and dispenser is $29.81 and $16.35
respectively. 
It was estimated by the NSW prison pharmacy that annual courier costs for transporting the
methadone to the prison clinics are $5500. This is based on a transportation cost of $2.00 per
kilogram.
Cost of methadone
The unit cost of methadone syrup was obtained from the Pharmaceutical Benefits Schedule (PBS)
(PBS). The NSW prison pharmacy distributed 18747 200ml bottles and 232 litre bottles of methadone
to prison clinics in 2002. Therefore the total cost of methadone syrup in 2002 was $147,080.
10
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The unit costs of the disposables used in the dosing of methadone are given in Appendix 1. It is
assumed that each methadone recipient uses one plastic cup per day. Each clinic administering
methadone uses one pair of gloves per day and two record books, one compete pump and one water
jug. The night safe used to store the methadone has a life of approximately 15 years (personal
communication with CMI Safe Co., supplier of drug safes to NSW Health). Therefore the annual cost
of the night safe is $67.
Salary on-costs
Twenty-six percent salary on-costs have been added to all salaries of Corrections Health Service
personnel (CHS finance department). 
Where appropriate, a 38 hour working week has been used.
Overheads
Overheads such as rent and electricity were excluded in this analysis. The methadone program
accounts for a relatively small proportion of total clinic time. The exclusion of overhead costs is
unlikely to have a significant effect on the overall cost of the program.
Unit costs
Unit costs have been collected from a range of sources including Corrections Health Service,
Department of Corrective Services and the Pharmaceutical Benefits Schedule. It should be noted
that CHS employees who come into frequent contact with inmates receive an additional
environmental/productivity allowance. The hourly rate of such staff is $2.11 above their NSW Health
department counterpart. Unit costs are shown in Appendix 1.
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Total cost of the program
The total cost of the prison methadone program in NSW is shown in Table 6.
Table 6: Total annual cost of the NSW prison methadone program
COMPONENT COST ($)
Nurse time 2,034,131
MO / DA doctor time 311,842
General CHS Admin 126,720
Management of the methadone program 246,284
Pharmacy + Courier 22,030
Disposables 22,702
Total CHS cost 2,763,709
Commonwealth costs (methadone) 147,080
Total cost of program 2,910,789
The total cost of the NSW prison methadone program is $2.9 million annually. It is important to note
that while different government bodies are responsible for the financing of the NSW prison
methadone program, the Commonwealth is responsible only for the cost of the methadone itself
(5%) and the NSW government, through CHS, is responsible for the remainder. The cost of the
methadone program to NSW Health is approximately $2.8 million. 
Cost per person year
This costing is based on the assumption that 900 inmates are receiving methadone maintenance
treatment in 21 NSW prisons. Therefore the annual cost per person year is $3,234, the NSW Health
portion of this is $3,071. 
Average cost per inmate
It is also possible to estimate the average cost per inmate. The average cost per inmate was
calculated by multiplying the daily cost of treatment by the average sentence duration. 
The NSW prison methadone study data was analysed to determine the average sentence duration
for inmates receiving methadone. The median sentence duration in the study was 60 weeks (1.2
years). However, it is likely that the average sentence duration of inmates in the study cohort is
greater than that of the general prison methadone population. One of the selection criteria of the
NSW methadone study was that inmates had a sentence duration great than four months. Therefore
it is likely that the study data were biased towards longer sentence duration.
To estimate the average cost per inmate correctly, it is necessary to re-examine the issue of
assessments. When estimating the overall cost of the program, 2590 nurse assessments and 762
doctors’ consultations were included in the analysis, despite the fact that only 900 inmates receive
methadone on a daily basis. These extra assessments and consultations were included in the
analysis because of the high number of inmates commencing or exiting the methadone program
during a 12 month period. 
To estimate the cost per inmate correctly, the model should allow for the fact that each inmate on
methadone receives an assessment by a nurse, at entry and at exit and one doctor consultation
during his/her sentence. Thus the average cost per inmate, based upon sentence duration of 1.2
years and a total of three assessments, is $3,708.
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The costs presented in Table 6 are the central estimate of the cost of the provision of the NSW prison
methadone program. Due to the variability in the provision of methadone, it is important to examine
the effect on the total cost of varying some of the assumptions used in the analysis. 
One of the key assumptions to be varied in the sensitivity analysis is the exclusion of costs associated
with correctional officers’ time. The costs associated with the correctional officers’ time have not
been included in the central estimate. However, the sensitivity analysis examines the effect on the
total cost of including the costs associated with correctional officers’ time in the analysis. Correctional
officers are involved in the methadone parade and the transportation of inmates to the clinic for
consultations. 
The sensitivity analysis examines that impact on the total cost of assuming that either two, three or
four correctional officers are occupied with the methadone parade in one hundred percent of prisons.
At least two correctional officers are present at the methadone parade in each prison. The number of
correctional officers present at the methadone parade will depend on both the security level of the
prison and how methadone is administered within that prison. It is usual for at least one correctional
officer to be present at the site of dosing and at least one officer to transport the inmates from their
cells/yard to the dosing. In two of the clinics observed, two officers were present at the site of dosing
and two officers were involved in transporting the inmates to and from dosing. In the other two prison
clinics observed, one officer was present at the site of dosing and one officer transported the inmates
to and from dosing. Therefore, it is usual for either two or four officers to be supervising the
methadone parade for the whole duration of the parade. 
Table 7 shows the number of correctional officers’ hours, per day and per inmate, associated with the
dosing of methadone in each of the observed clinics. As already discussed, the use of a weighted
average was deemed inappropriate.  
Table 7: Hours of correctional officer time associated with dosing
PRISON NO. PATIENTS DURATION NO.OFFICERS OFFICER HOURS  OFFICER HOURS  MINUTES
PER DAY PER INMATE PER INMATE
A4 12 48 0.195 11 mins 42 secs
B 100 3.5 4 14 0.140 8 mins 24 secs
C6 1 3.5 2 7 0.115 6 mins 54 secs
D1 3 0.875 2 1.75 0.135 8 mins 6 secs
Total 215 0.146 8 mins 46 secs
In 2003, 900 inmates received methadone daily. Assuming an average of three correctional officers, a
total of 131.51 hours per day of correctional officers’ time is spent supervising the methadone
parade. It is estimated that, in total, 48001 hours of correctional officers’ time per annum is spent
transporting inmates to and from the methadone parade. 
It is estimated that correctional officers transport inmates to 3352 methadone-related assessments
per year. In 2001, 762 inmates commenced methadone whilst in custody (CHS Annual Report). These
inmates would require both a nurse assessment interview and a doctor consultation. In addition,
1,828 inmates were released into the community on methadone. These inmates would also require
an assessment with a nurse. It is estimated that each assessment interview with a nurse requires 45
minutes of one correctional officer’s time (30 minutes for the assessment and 15 minutes for
transportation) and each doctor consultation requires 25 minutes of one correctional officer’s time
(10 minutes for the consultation and 15 minutes for transportation).  Therefore 2260 hours per year
are spent transporting inmates to assessments. The annual salary of a correctional officer grade 5/6
is $57,123. Therefore the hourly rate of a correctional officer is $28.91. Thirty-two percent salary on-
costs have been added to all salaries of personnel from the Department of Corrective Services (DCS
recruitment). 
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As can been seen in Table 8, variation in the resource use in terms of time and number of staff
present makes a significant difference to the cost.
Table 8: Sensitivity analysis
ASSUMPTION TOTAL PERCENT  COST PER PERSON
COST ($) CHANGE (%) YEAR ($)
Total cost of the NSW prison methadone program 2,910,789 3,234
Include all CHS administration costs 2,952,234 1% 3,280
Low estimate: 4 mins per inmate 2,512,350 -14% 2,792
High estimate: 8 mins per inmate 3,624,418 25% 3,627
Low estimate: 3 mins per inmate 2,760,430 -5% 3,067
High estimate: 14 mins per inmate 3,083,314 6% 3,426
Two Officers present at dosing 4,303,611 48% 4,782
Three Officers present at dosing 4,828,716 66% 5,365
Four Officers present at dosing 5,610,194 93% 6,234
Low estimate: 7 mins per inmate 4,435,501 52% 4,928
High estimate: 12 mins per inmate 5,442,933 87% 6,048
Comparison with community methadone programs
The annual cost of the NSW prison methadone program has been shown to be $3,234 per person
year, the NSW Health portion of this is $3,071. 
This analysis suggests that the NSW prison methadone program compares favourably to community
methadone programs. There are several reasons why prison methadone programs are likely to be
more costly than community methadone programs. These reasons relate to the administration of the
program and operational set-up of a prison facility. Prison methadone programs are likely to have
higher operating costs than community methadone programs due to the type of patients receiving
treatment, the setting in which treatment is given and the high turnover of patients (due to entry and
exit from prison and transfers between prisons). 
Access
Costs associated with nursing time are likely to be higher for prison methadone due to the additional
security requirements surrounding the provision of methadone in a prison setting. Due to the high
security within prisons, it is not possible for methadone patients to simply present at the clinic freely
to collect their treatment. There are several reasons why the dosing parade takes up a large
proportion of the morning. Firstly, in some prisons the nursing staff move around the prison since
dosing is performed in satellite clinics or in the wings themselves. Therefore a significant amount of
time is spent moving from one dosing area to the next. Secondly, there is often a substantial amount
of time spent waiting for the inmates to arrive at the dosing area. The nursing staff are required to
wait whilst the officers return the inmates from one wing and collect the inmates from the next wing.
In some prisons this waiting time between wings can be as much as 10 minutes. Such issues are
likely to increase nurse time and thus increase operating costs.
Administration costs of entries, exits and transfers
During any one year, there is a high turnover of patients on prison methadone programs. New
inmates are continuously entering prison and existing patients are continuously being released from
the prison environment. In addition, inmates are regularly transferred between prisons. It was
estimated that the NSW prison methadone program has a turnover rate of nearly 20% per month
(Personal communication, Chief Executive Officer of CHS). Such high level of patient turnover is
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Management of transitory inmates
The NSW prison methadone program also provides nightly methadone to detainees in NSW police
cells. This group of inmates are very transitory and thus a significant amount of work is associated
with providing methadone to these inmates. The administrative costs of the NSW prison methadone
program could be significantly reduced if this group of inmates was not included in the program.
Even though these inmates are not directly included in this analysis, the cost of providing methadone
to these inmates will cause the administration costs of the program to be greater than if these
inmates were not included in the program.  
However, in spite of these complications, the NSW prison methadone program compares favourably
to community methadone programs. NSW Health estimates that the cost per year in 1999 dollars for
community methadone is $3098 (personal communication, NSW Health), and the National
Evaluation of Pharmacotherapies for Opioid Dependency (NEPOD) found that the cost per year for
methadone at selected specialist clinics was $3861 in 1998 dollars (Mattick, Digiusto et al. 2001). If
the Health Price Index is used to inflate these costs to 2003 dollars, the annual cost of providing
methadone in the community is $3,514 per client and $4,493 per client in specialist clinics.16
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5. COST OFFSET ANALYSIS (THRESHOLD ANALYSIS)
In the context of methadone treatment, there are several possible treatment outcomes that could be
included in a cost-effectiveness analysis. Firstly, there appears to be the general consensus that
heroin use is linked with higher levels of criminal activity (Hall 1996). Therefore, it is assumed that
regular methadone treatment, and hence reduced heroin use, will reduce drug-related crime and
thus result in fewer episodes of re-incarceration once inmates are released (Hall, Ward et al. 1998).
Secondly, prison methadone treatment may, through reduced needle sharing, reduce the incidence
of HCV within the IDU population. Therefore, an economic evaluation of prison methadone ideally
would incorporate either avoided incidence of HCV or avoided re-incarceration, once inmates are
released, as the outcomes associated with treatment.
However, there is little evidence in the literature relating to HCV incidence and re-incarceration rates
for those patients receiving methadone maintenance therapy in prison. In addition, the effectiveness
data from the NSW prison methadone follow-up study was not suitable for comparing the cost-
effectiveness of methadone since there was no control arm.
In the absence of any definitive outcomes data relating to HCV incidence and re-incarceration rates of
prison methadone recipients, a threshold analysis was undertaken. A threshold analysis identifies
the effectiveness threshold that is required, given the cost of the intervention, to render the
intervention cost-effective relative to the comparator. In this analysis, the threshold analysis was
undertaken to determine the point at which the methadone program would be cost neutral to
government.
The two possible treatment outcomes associated with prison methadone, avoided HCV and avoided
re-incarceration, are measured in substantially different units. It is not possible to combine avoided
cases of HCV and avoided days of re-incarceration in the same analysis without converting these
benefits into one single measure (usually measured in monetary units).
Therefore, a threshold analysis which includes two outcomes that are usually measured in different
units will need to convert the treatment outcomes into monetary units. In the context of this report,
the benefits associated with prison methadone treatment are the savings that are accrued by
avoiding cases of HCV and avoiding re-incarceration once the inmate is released.
A model was constructed that identifies the level of effectiveness required from methadone
treatment, in terms of avoided cases of HCV and avoided re-incarceration, to offset the costs of the
treatment itself. The model was based on the NSW methadone program for 1000 inmates receiving
methadone treatment for one year. The model produces two separate calculations. Firstly it
calculates the number of incarceration days per patient that one year’s methadone treatment must
avoid in order to offset the cost of the treatment. Secondly, the model combines avoided cases of
HCV and avoided re-incarceration to determine the number of re-incarceration days that must be
avoided to offset the cost of the methadone treatment if the number of incident cases of HCV avoided
by methadone treatment is fixed. 
Cost of incarceration
The daily cost of incarceration is shown in Table 9. The percentage of the NSW trial cohort in
minimum, medium, maximum and unknown security was 18%, 13%, 15% and 54% respectively
(Dolan, Shearer et al. 2003). The average daily cost of incarceration was calculated by multiplying the
unit cost for each security level by the proportion of the cohort in each particular security level. It was
assumed that those inmates with unknown security level in the trial were housed in medium security
prisons. The average daily cost of incarceration was estimated at $176.23.17
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Table 9: Unit cost of incarceration
TYPE OF PRISON COST PER DAY YEAR
Maximum security  $208.13 2001/2
Medium security  $168.59 2001/2
Minimum security  $165.14 2001/2
Source of data: DCS Annual report 
Cost of treating HCV
A literature search was performed to identify the cost savings associated with avoiding incident cases
of HCV. In the core analysis, the threshold analysis assumes that one year of methadone treatment
has the potential to prevent cases of HCV. This assumption was based on the fact that, although not
statistically significant, the difference in HCV incidence seen in the Dolan study has persisted through
the four years of follow-up, despite the fact that the difference in methadone treatment was only four
months. Thus in the core analysis, the cost savings associated with avoiding a case of HCV is equal to
the lifetime cost of treating a person with HCV.  In the sensitivity analysis, it is assumed that one year
of methadone treatment does not avoid seroconversion but simply delays seroconversion by one
year. Thus in the sensitivity analysis, the cost savings associated with delaying a case of HCV by one
year is estimated by deferring the lifetime cost by one year. 
The lifetime cost of treating HCV is taken from Shiell et al (Shiell and Law 2001). The Shiell paper
assumes that not all newly diagnosed HCV patients incur expensive healthcare costs; that, for every
1000 people infected, 250 will incur no healthcare costs, 642 people will suffer chronic infection 
but have no substantial long-term problems and that 108 people will develop severe complications
and have extensive healthcare requirements (Shiell and Law 2001), and includes only direct
healthcare costs.
Shiell estimates that the discounted lifetime cost of treating HCV is $6000. It is likely that Shiell’s
estimate is conservative relative to current costs. All costs in the paper are expressed in 1996
Australian dollars. If the Health Price Index (AIHW) is used to inflate to 2002 dollars, the cost
increases to $7067. Secondly, HCV is assumed to be treated with interferon monotherapy. Current
treatment is usually a combination of pegylated interferon plus ribavirin. Combination interferon is
known to be more expensive than monotherapy. 
In the sensitivity analysis, in order to determine the cost savings associated with delaying
seroconversion by one year, the lifetime cost (Shiell and Law 2001) was deferred by one year. The cost
savings is equal to the difference between the current lifetime cost and the deferred lifetime cost,
discounted by 5%. Thus the cost savings associated with delaying seroconversion by one year is
approximately $286. 
Since it is possible that the Shiell paper underestimates the current lifetime cost of treating HCV, the
sensitivity analysis also examines the effect of doubling the Shiell estimate. 
Single-outcome threshold analysis - avoided re-incarceration
The annual cost of methadone treatment per inmate year is $3,234. The model assumes that 1000
inmates receive prison methadone treatment for one year. The model identifies the number of 
re-incarceration days that must be avoided to offset the cost of the methadone treatment. In other
words, the model compares the cost of methadone treatment with the cost savings realised from
avoiding days of re-incarceration. The model then identifies the number of days of re-incarceration
that must be avoided to equate the cost of treatment with the cost savings accrued. 18
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Data from the NSW prison methadone follow-up study suggests that 7.3 percent of the cohort were
not released in the study timeframe and therefore were unable to be re-incarcerated. Therefore
those never released from prison are excluded from the re-incarceration analysis. Thus it was
possible for methadone treatment to avoid re-incarceration in 92.7% of the cohort. Of those 1000
inmates receiving methadone, 927 will be released from prison and thus have the chance of 
re-incarceration. Assuming a daily incarceration cost of $176.23, methadone treatment must avoid
18352 days of re-incarceration to offset the annual cost of treatment for 1000 inmates or, to put it
another way, if re-incarceration is delayed by 20 days for every inmate on the methadone program
who is released from jail, the cost of the methadone program for 1000 recipients is offset. That is, 
for a year of prison methadone for an inmate to be cost-neutral, on average 20 days of 
re-incarceration would need to be avoided (which may result from reduced rates of re-offending 
or from a delay in re-offending).
Combined-outcome threshold analysis - avoided re-incarceration and avoided HCV incidence
An additional outcome from methadone treatment is avoiding incident cases of HCV. The NSW
prison methadone data suggests that the incidence of HCV in the methadone treated cohort is
approximately half that of the untreated cohort. The data suggests that the incidence of HCV in
methadone treated inmates is 24 per 100 person years. The incidence of HCV in non treated IDU is
32 per 100 person years. Thus methadone treatment avoided 8 cases of HCV per 100 person years.
If cases of HCV are avoided through methadone treatment, there are also cost offsets from this. This
reduces the required number of days of re-incarceration avoided for the program to be cost neutral.
The combined-outcome threshold analysis assumes that 1000 inmates receive methadone
treatment for one year and that methadone treatment avoids both days of re-incarceration and cases
of HCV. In the model, the number of incident cases of HCV avoided by methadone treatment is fixed,
and the number of re-incarceration days that must be avoided to offset the cost of the methadone
treatment is calculated. In other words, the model compares the cost of methadone treatment with
the cost savings realised from avoiding days of re-incarceration and avoiding a given number of
cases of HCV. The model then identifies the number of days of re-incarceration that must be avoided
to equate the cost of treatment with the cost savings accrued. 
The combined-outcome threshold analysis assumes that the difference in HCV incidence as seen in
the NSW prison methadone study is representative of prison methadone treatment and that the
control arm of the trial is comparable to no treatment (i.e. a delay in methadone treatment can
represent no treatment). Thus, the model assumes that the reduction in HCV incidence is fixed at 
the level observed in the NSW prison methadone study data. Therefore it was assumed that
methadone avoids 0.8 HCV cases per person year. The threshold analysis identifies the number of
avoided re-incarceration days required, when combined with this level of avoided HCV incidence, to
offset the cost of the program. 
The NSW prison methadone data suggests that 71.7 percent of the cohort is already HCV positive at
the time of starting prison methadone and thus it is only possible for methadone treatment to avoid
seroconversion in 28.3% of the cohort. Therefore those inmates who are already HCV positive are
excluded from the HCV analysis. 
Of those 1000 inmates receiving methadone, 283 will be HCV negative at the time of starting prison
methadone treatment and thus have the chance of avoiding seroconversion. Since methadone avoids
0.8 cases per person year, the model assumes that one year’s methadone treatment avoids
approximately 23 incident cases within the year. Assuming the discounted lifetime cost of treating
HCV is $6,000 and the daily cost of re-incarceration is $176.23, the model predicts that methadone
treatment must also avoid in total 17581 days of re-incarceration to fully offset the cost of treatment.
This equates to approximately 19 days avoided re-incarceration per inmate (able to be re-
incarcerated) per year to offset the cost of the program. 19
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Threshold analysis – Sensitivity analysis
The central estimate assumes that one year of methadone treatment has the potential to prevent
cases of HCV. In the sensitivity analysis, it is assumed that one year of methadone treatment does not
avoid seroconversion but simply delays seroconversion by one year. Thus in the sensitivity analysis,
the cost savings associated with delaying a case of HCV by one year is estimated by deferring the
lifetime cost by one year. Assuming the cost savings associated with delaying seroconversion by one
year are $286, 20 days of re-incarceration must be avoided to offset the cost of the program.
In addition, the sensitivity analysis examines the effect of doubling the Shiell estimate. Assuming the
cost savings associated with avoiding a case of HCV are $12,000, 18 days of re-incarceration must be
avoided to offset the cost of the program.
Conclusions drawn from the threshold analysis
The results from the combined-outcome threshold analysis are not substantially different to the
results from the single-outcome threshold analysis. The single-outcome threshold analysis suggests
that, per 1000 recipients, it is necessary to avoid 20 days of re-incarceration per inmate (able to be re-
incarcerated) in order for the total costs of the treatment to be offset. The combined-outcome
threshold analysis suggests that, per 1000 recipients, if 12 month’s methadone treatment avoids
approximately 23 incident cases of HCV, it is necessary to avoid 19 days of re-incarceration per
inmate (able to be re-incarcerated) in order for the total costs of the treatment to be offset. Thus both
analyses show that, irrespective of whether avoided cases of HCV are included in the analysis,
approximately 20 days of re-incarceration must be avoided to offset the cost of methadone treatment.
A literature review was performed to determine the feasibility of prison methadone avoiding 20 days
of re-incarceration once inmates are released. No evidence relating to the effectiveness of prison
methadone could be identified in the literature. However, a small number of papers relating to
community methadone programs have examined the effectiveness of methadone in avoiding
criminal activity and re-incarceration. Hall reviews evidence from 5 randomised controlled trials, 
4 comparative observational studies and 4 pre-post treatment studies (Hall, Ward et al. 1998). 
The findings of the review suggest that the relationship between methadone maintenance and a
reduction in criminal behaviour, in terms of both self-reported behaviour and official records of
convictions, is a reasonably strong one. It was concluded that “a relationship between methadone
treatment and reduced drug use and criminal behaviour has been consistently observed in controlled
trials, quasi-experimental studies, comparative studies, and pre-post studies in the USA, Sweden,
Hong Kong and Australia”.
There appears to be no evidence in the literature regarding the likelihood that the provision of
methadone maintenance will result in 20 days of re-incarceration being avoided. However, there is
reasonably strong evidence to suggest that criminal behaviour among methadone recipients is
significantly less than their untreated counterparts. Therefore it is not unreasonable to assume that a
well managed methadone maintenance program has the ability to significantly reduce the costs
associated with re-incarcerating this group of individuals.  6. DISCUSSION
This study represents the first appraisal of the costs and cost-effectiveness of a methadone
maintenance program within a prison setting. Several issues arose whilst performing this analysis
that prevented the completion of a ‘standard’ cost-effectiveness analysis. However, the costing
analysis suggests that the annual cost of the NSW prison methadone program compares favourably
to community methadone programs. 
This study was performed using a government perspective, rather than the broader societal
perspective. If a societal perspective were taken, other costs, such as costs of crime, would be
included in the analysis. Cost of crime, such as court costs, policing costs and costs to victims of
crime could be substantial. It is likely that these costs of crime would dominate even the healthcare
costs. Thus it is possible that a cost-effectiveness analysis of prison methadone performed using a
societal perspective would result in a favourable cost-effectiveness ratio.  
In this analysis, the annual cost of the methadone program is based on observational visits to four
prisons. There was considerable variability among prisons in relation to how the methadone was
administered. The actual dosing of methadone was either performed at the central clinic, at satellite
clinics or in the wings themselves. In addition, the number of correctional officers present also varied
between prisons. Therefore the cost of administering the methadone program will vary depending on
which model is being costed. 
This variability amongst prisons may reduce the generalisability of these results. Since most of the
costs of the program are incurred at the point of methadone administration, the relative cost-
effectiveness of each program will depend on the methods of administration and organisational
arrangements of the program being assessed. The organisational arrangements and administering
of methadone varies considerably between prison and no doubt between programs. Thus prison
methadone programs could be more or less costly in different settings. 
The relative cost-effectiveness of methadone will depend upon the prevalence of HCV within the
population being studied. The results from the Dolan follow-up study suggest that methadone
treatment prevents HCV seroconversion (although this difference was not statistically significant). It is
likely that this difference did not reach statistical significance due to the high baseline prevalence of
HCV in the study population. In the Dolan trial baseline HCV prevalence was high (above 70%). As a
result, there was only a small chance of preventing HCV seroconversion. In a younger population
prevalence of HCV would be lower. Thus methadone treatment would have the potential to avoid
more cases of HCV seroconversion. Therefore it is likely that an assessment of prison methadone in
younger inmates would result in a more favourable cost-effectiveness ratio.
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CATEGORY ACTIVITY UNIT UNIT COST YEAR  SOURCE
Practicing medical staff Nurses pay (RN8) Per hour 28.12 2003 NSW + allowance
Medical Officers (CMO) Salary 110,942  2003 NSW + allowance
Per hour 56.14 2003 Based on above
Visiting Medical officer Per hour 146.75 2003 NSW + allowance
Drug and Alcohol staff specialist Salary 107,929  2003 Based on below
Per hour 54.62 2003 NSW + allowance
D+A director Per hour 62.11 2003 Estimated from 
NSW Health
Liaison nurse (CNC) Per hour 35.98 2003 CHS
D+A CNC Per hour 35.98 2003 CHS
Pharmacotherapy CNC Per hour 35.98 2003 CHS
Liaison administrator Per hour 15.69 2003 Estimated from 
NSW Health
Information officer Per hour 21.76 2003 CHS
Other Pharmacist Per hour 29.81 2003 CHS finance dept
Pharmacy dispenser Per hour 16.35 2003 CHS finance dept
Courier  Per annum 5500 2002 CHS pharmacy
Correctional officers  Salary 57,123 2003 DCS
Per hour 28.91 2003 Based on above
CHS Admin IT, payroll, finance Per annum 3,693,040  2002 8% of total CHS
budget
Salary on-costs CHS On-costs Percent increase 1.26 CHS finance dept
DCS On-costs Percent increase 1.31 CHS finance dept
Methadone 200ml bottle 7.4 2003 PBS
Methadone 1 Litre bottle 36 2003 PBS
Plastic cups Per item 0.0354 2003 CHS stores
Plastic gloves Per item 0.0515 2003 CHS stores
Compete pump Per item 395 2003 CHS stores
Record books Per item 20 2003 CHS stores
Water jug Per item 6.84 2003 CHS stores
Safe, small size Per item 1000 2003 CHS stores
Equipment 2 computers Per item 2000 2003 Office suppliers
FAX machine Per item 800 2003 Office suppliers
Per sheet 0.1 2003 Office suppliers
Per call 0.4 2003 Office suppliers
Photocopier Per item 8000 2003 Office suppliers
Per sheet 0.1 2003 Office suppliers
All unit costs where the source is cited NSW Health are taken from
http://www.health.nsw.gov.au/er/human_resources/hs_awards/hsawards_index.html
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